Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
-
br PFL AE as a model
2020-11-17
PFL-AE as a model for the GRE–AEs Most of the GRE–AEs have proven difficult to study due to instability, difficulty in overexpression, lability of the iron-sulfur cluster, or other reasons. PFL-AE is the exception, and after the initial discovery of the iron–sulfur cluster in this enzyme [60], co
-
CYP A and CYP D are among the main
2020-11-16
CYP3A4/5 and CYP2D6 are among the main drug-metabolizing enzymes in humans that are responsible for the metabolism of more than 50% of marketed drugs [19], [21]. Drugs metabolized by CYPs are prone to drug–drug interactions, thereby modifying their response [18], [32]. Metabolic inhibition is also i
-
br Conclusion br Introduction br CRL
2020-11-16
Conclusion Introduction CRL4 E3 ligases in tumorigenesis Small molecule-based PROTACs PROTAC: Major biological impacts Acknowledgements The authors sincerely apologize to all those colleagues whose important work was not cited in this paper owing to space limitations. They thank th
-
mtor inhibitor The E enzyme is the apex
2020-11-16
The E1 enzyme is the apex for downstream enzymatic cascades and signaling pathways mediated by Ub and Ub-like proteins (Ubls) (Pickart, 2001). Studying characteristics of E1 and its catalytic functions may throw light to the role of ubiquitination in cell development. All known eukaryotic E1 are mon
-
Of note BRQ and LFM are two well known
2020-11-16
Of note, BRQ and LFM are two well-known immunosuppressive agents (Batt, 1999). As for LFM, it was reported as immunosuppressive therapy for bone marrow (Avery et al., 2004) and renal (Chon and Josephson, 2011) transplantation. Accumulating evidence indicated that organ transplant patients irrelevant
-
Real time PCR as described previously with minor modificatio
2020-11-16
Real-time PCR, as described previously with minor modifications, was used to detect DNA . The PCR mixture (Qiagen) was as follows: 5mM MgCl2, 2.5μl of 10x PCR Buffer, 0.125μl of HotStarTaq DNA Polymerase, 0.25mM of each dNTP, 0.4μM of each primer and 0.1μM of FAMlabelled probe (‘5-aacaattggagggcaagg
-
A series of monocarboxylated chalcones e g compounds
2020-11-16
A series of monocarboxylated chalcones (e.g. compounds 7 and 8, Fig. 2A) was previously identified as good CysLT1 antagonists [20], and none of them exhibited CysLT2 antagonistic activities (Supplementary Table S1). This study was consistent with reported result that CysLT2 P7C3 was not sensitive t
-
To date methods for the simultaneous analysis of
2020-11-16
To date, methods for the simultaneous analysis of multiple probe drugs in the plasma have been described by using HPLC-DAD or LC–MS/MS. Although previous cocktail methods have used combinations of those four or other probe drugs with LC–MS/MS methods, most of those studies focused on only the analys
-
Based on the finding described
2020-11-16
Based on the finding described above, the present study was designed to investigate the effects of specific CRF receptors, CRF1 and CRF2, in the BLA and CeA on the duration of TI in guinea pigs (Cavia porcellus). To this end, we evaluated whether administration of the CRF1 WAY-100635 maleate salt a
-
br Limitations of the study br Possible conflicts of interes
2020-11-16
Limitations of the study Possible conflicts of interest Dr. Fayemiwo or SAF has received full financial support from Europe Gilead Sciences Ltd. for his M.Sc. degree programme in Medical Mycology and has been paid for talks on behalf of AstraZeneca and GSK. Caroline Moore or CBM has received
-
Many studies have shown that
2020-11-16
Many studies have shown that curcumin delays the progression of atherosclerosis in different atherosclerotic animal models [18], [19], [20], [37] and the risk of atherosclerosis in human studies [15], [38], [39]. Curcumin also has many properties that contribute to combat atherosclerosis, such as an
-
Ion Channel Compound Library receptor The genetic basis of r
2020-11-16
The genetic basis of resistance to dieldrin has been described for several insect species as a mutation in the transmembrane domain II of the GABA-Cl or rdl (resistance to dieldrin) gene (ffrench-Constant et al., 2004; Bass et al., 2004; Du et al., 2005). A mutation in the GABA-Cl gene was found at
-
br Discussion We are reporting a cryptic insertion of
2020-11-14
Discussion We are reporting a cryptic insertion of chromosome 22 material (EWS) to the long arm of chromosome 11 (11q24, FLI-1) recognizable by FISH in RN 1734 synthesis exhibiting trisomy 8 as the sole cytogenetic anomaly. In ES and PNET tumors, trisomy 8 is the most common secondary abnormalit
-
br Results and discussion br Conclusions In conclusion we ha
2020-11-14
Results and discussion Conclusions In conclusion, we have developed rational strategies that allowed us to successfully identify a series of novel analogs structurally related to to modulate the activity of estrogen-related receptors (ERRγ and ERRβ), which are constitutively active. All of the
-
Cy3 carboxylic acid (non-sulfonated) PGE EP activation has b
2020-11-14
PGE2-EP4 activation has been found to attenuate the activation of microglia and to prevent lipid peroxidation and pro-inflammatory gene expression in a murine model of lipopolysaccharide (LPS)-induced Cy3 carboxylic acid (non-sulfonated) inflammation [15]. Moreover, PGE2/EP4 signaling has elicited
15226 records 721/1016 page Previous Next First page 上5页 721722723724725 下5页 Last page